LWJ-M30, a conjugate of DM1 and B6, for the targeted therapy of colorectal cancer with improved therapeutic effects.

Colorectal cancer (CRC) is one of the most prevalent cancers worldwide as well as a significant cause of mortality. The conventional treatment could cause serious side effects and induce drug resistance, recurrence and metastasis of cancers. Hence, specific targeting of cancer cells without affecting the normal tissues is currently an urgent necessity in cancer therapy.

XHL11, a novel selective EGFR inhibitor, overcomes EGFR-mediated resistance in non-small cell lung cancer.

The first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib significantly improved the therapeutic effect in non-small cell lung cancer (NSCLC) patients with EGFR mutation. However, the EGFR mutation occurs and results in acquired resistance. Consequently, mutant selective third-generation EGFR TKIs represented by AZD9291 (Osimertinib) have been developed to offer more effective therapeutic treatment, but the clinical application is limited by the acquired resistance and the high costs.

[Meta analysis of association between TNF-α-308 polymorphism and periodontitis in Chinese Han population].

Purpose: To assess the association between TNF-α-308 polymorphism and periodontitis in Chinese Han population.

Methods: Articles published between 1994 and 2011 were searched in the fulltext database of CNKI, Chinese Biomedical Literature Database, Wanfang Database and PubMed. Case-control studies on TNF-α-308 polymorphism and periodontitis were searched up to Feb.